Articles related to SCHIZOPHRENIA

This groundbreaking study from Northwestern Medicine unveils a surprising interaction of antipsychotic drugs with neurons, prompting a revision of our understanding of psychosis treatment and opening new pathways for more effective, safer drugs.

NEW YORK CITY | THE GLASSHOUSE CHELSEASATURDAY, JUNE 24, 2023 In a comprehensive in-person setting, psychiatrists will get current, clinically relevant, and practice-based updates. This full-day conference will feature interesting presentations conducted by renowned thought leaders in schizophrenia, postpartum depression, major depressive disorder, ADHD, and addiction. Each session will include a patient perspective to ensure professionals obtain practical, real-world understanding.

Poor adherence to treatment is the biggest predictor in relapse in serious mental illnesses. In this 0.5-CME credit activity, the panel discusses key contributors to the adherence challenge and strategies for improving adherence – including use of newer, better tolerated therapies. Available in video, podcast, and text.

Lumateperone 42 mg/d is effective in the treatment of schizophrenia and has no clinically significant effects on body weight, metabolic variables, motor function, the ECG QT interval, or prolactin levels, with a likelihood to be helped or harmed (LHH) much greater than 1 when comparing therapeutic response to these tolerability/safety outcomes. When comparing therapeutic response versus a somnolence/sedation AE, lumateperone appears to be associated with somnolence/sedation, and LHH approaches 1. In indirect comparisons with other antipsychotics, this somnolence/sedation AE profile is not dissimilar; however, the absence of weight gain, glucose/lipid abnormalities, and akathisia, as well as the absence of prolactin elevations, distinguishes lumateperone.

The development of effective new therapies has been challenging. This discovery of calcium signaling as a central abnormality in schizophrenia neurons is an exciting new finding, since available antipsychotics treat only positive symptoms and are not effective for all patients.

For the treatment of psychosis in schizophrenia, may an oral molecule constitute a new class of psychotropic drug with a non-D2-receptor binding mode of action? The purpose of a recent study was to answer that question, which Dr. Matt Birnholz delves into in this audio abstract.